// App-Quantinova.ai

e21020 : Association of baseline and longitudinal low neutrophil-lymphocyte ratio (NLR) and high lymphocyte counts (LCs) with progression-free survival (PFS) and overall survival (OS) in real world advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with nivolumab (nivo) or pembrolizumab (pembro).

Researchers

Presenter

  • Stephanie Labomascus

Principal Investigators

  • Ibtihaj Fughhi

  • Andrew McDonald

  • Philip D. Bonomi

  • Marta Batus

  • Mary J. Fidler

  • Sanjib Basu

  • Jeffrey Allen Borgia

Medical Centers

  • Rush University Medical Center, Chicago, IL

  • Rush Medical College, Chicago, IL

  • University of Chicago, Section of Medical Oncology Rush University Medical Center, Chicago, IL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Neutrophil lymphocyte ratio

Drug/Treatment

  • Pembrolizumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved